Company intelligence / Profile preview

ZipBio

Seattle, Washington, USAziptx.bio ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

ZipBio has recently launched with a proprietary generative AI-driven COMPACT platform to design novel, compact therapeutic proteins. The company has not yet reported clinical results or advanced any programs into human trials but has raised $4 million in seed funding to support its preclinical research efforts[2].

Modalities: De novo-designed proteinsGene therapiesBiologics
Industry: Biotech

Beyond the preview

Go deeper on ZipBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZipBio.

Explore the full profile